PRO MEDICUS LIMITED (PME)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

PME

PME - PRO MEDICUS LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.01
Index: ASX100 | ASX200 | ASX300 | ALL-ORDS | ALL-TECH

Pro Medicus is an imaging IT company providing a range of radiology software and services, medical accounting and clinical reporting to the health care sector. Founded in 1983, the company listed on the ASX in 2000.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$179.24

27 Aug
2026

-5.360

OPEN

$184.50

-2.90%

HIGH

$187.67

361,096

LOW

$179.02

TARGET
$228.333 27.4% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AVE . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CTE . CU6 . CVB . CYC . EBR . EIQ . EMV . EYE . FPH . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . RAP . RMD . SHG . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
PME: 1
Title FY25
Actual		 FY26
Actual		 FY27
Forecast		 FY28
Forecast
EPS (cps) xxx 254.0 196.2 xxx
DPS (cps) xxx 69.0 93.5 xxx
EPS Growth xxx 100.0% - 22.8% xxx
DPS Growth xxx 25.5% 35.5% xxx
PE Ratio xxx N/A 92.5 xxx
Dividend Yield xxx N/A 0.5% xxx
Div Pay Ratio(%) xxx 27.2% 47.7% xxx

Dividend yield today if purchased 3 years ago: 0.94%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.38

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 26/02 - ex-div 32.00c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202120222023202420252026
EPS Basic xxxxxxxxxxxxxxx254.0
DPS All xxxxxxxxxxxxxxx69.0
Sales/Revenue xxxxxxxxxxxxxxx261.7 M
Book Value Per Share xxxxxxxxxxxxxxx431.6
Net Operating Cash Flow xxxxxxxxxxxxxxx136.5 M
Net Profit Margin xxxxxxxxxxxxxxx101.40 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202120222023202420252026
Return on Capital Employed xxxxxxxxxxxxxxx74.97 %
Return on Invested Capital xxxxxxxxxxxxxxx74.65 %
Return on Assets xxxxxxxxxxxxxxx55.93 %
Return on Equity xxxxxxxxxxxxxxx74.97 %
Return on Total Capital xxxxxxxxxxxxxxx55.06 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx71.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202120222023202420252026
Short-Term Debt xxxxxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxxxxx1 M
Total Debt xxxxxxxxxxxxxxx2 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx251 M
Price To Book Value xxxxxxxxxxxxxxx47.13

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202120222023202420252026
Capex xxxxxxxxxxxxxxx8.7 M
Capex % of Sales xxxxxxxxxxxxxxx3.32 %
Cost of Goods Sold xxxxxxxxxxxxxxx51 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx15 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx189 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.9

No. Of Recommendations

6
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgan Stanley

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

19/08/2026

2

Accumulate

$230.00

28.32%

Morgans believes Pro Medicus's FY26 result shows the company is executing at an even higher level than the market was ascribing to the stock.

In FY26, EBIT margin was 74.9% and constant currency EBIT growth came in at 30.6%, both beating expectations.

FY27 is positioning to be another "stand out year" the analyst states with four Trinity and 15 other implementations already in the bag. Forward contracted revenue rose 41.3% to $1.34bn and the five-year CAGR stands at 29%.

The analyst views the FY27 revenue expectation of around $335m as less speculative than a few months ago.

The stock remains Accumulate rated with a $230 target and is viewed by the broker as one of the highest-quality businesses on the ASX.

FORECAST
Morgans forecasts a full year FY27 dividend of 97.00 cents and EPS of 250.00 cents.
Morgans forecasts a full year FY28 dividend of 120.00 cents and EPS of 309.00 cents.

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Moelis

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Canaccord Genuity

13/05/2026

1

Buy

$168.62

-5.93%

Canaccord Genuity maintains a Buy rating for Pro Medicus and reduces the target price to $168.62 from $180.82 following a review of the company's valuation relative to sector-wide multiple compression.

Revenue forecasts have been revised down by -8% for FY26 and -11% for FY27 to reflect lower data migration revenue and a higher AUD:USD exchange rate headwind.

The broker notes underlying fundamentals remain exceptional, with the business expected to deliver growth exceeding 20% on both the top and bottom lines despite negative sector sentiment.

Large contract wins yet to materialise in the profit and loss statement underpin significant earnings momentum for FY27 and FY28.

Mispricing is evident as market volatility masks the value of businesses with high excess cash returns, according to the report.
Access Extra Coverage Research History >

PME STOCK CHART

FNArena News on PME

1
Next Week At A Glance 24-28 Aug 2026

Aug 21 2026 - Weekly Reports
2
Australian Broker Call *Extra* Edition – Aug 20, 2026

Aug 20 2026 - Daily Market Reports
3
FNArena Corporate Results Monitor – 19-08-2026

Aug 19 2026 - Australia
4
Rudi Interviewed: Bear Market Be Gone

Aug 13 2026 - Rudi's View
5
Rudi’s View: Final Preparations For August

Aug 05 2026 - Rudi's View

Latest Medical Equipment & Devices News

1
Rudi Interviewed: Bear Market Be Gone

Aug 13 2026 - Rudi's View
2
Are Headwinds Building For ResMed In FY27?

Jul 14 2026 - Australia
3
A Technical Breakout For ResMed

Jul 07 2026 - Technicals
4
Awaiting Catapult Sports’ Fundamental Re-Rating

Jun 15 2026 - Small Caps
5
Treasure Chest: Pro Medicus

Jun 04 2026 - Treasure Chest
6
Cochlear’s Shock Downgrade Raises Concerns

Apr 23 2026 - Australia
7
GLP-1s Drive Strong Quarter For ResMed

Feb 02 2026 - Australia
8
ImpediMed Ready To Scale Up

Dec 16 2025 - Small Caps
9
Fisher & Paykel Healthcare’s Superior Profile

Dec 02 2025 - Australia
10
4DMedical Poised For A Recovery

Nov 25 2025 - Technicals